TRIB Stock Risk & Deep Value Analysis
Trinity Biotech plc
Healthcare • Medical Devices
DVR Score
out of 10
The Bottom Line on TRIB
We analyzed Trinity Biotech plc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TRIB through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈TRIB Performance Overview3yr weekly
Unlock TRIB Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
TRIB Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Trinity Biotech plc (TRIB)
Sector
Healthcare
Industry
Medical Devices
Market Cap Category
small
Market Cap
$15.30M
TRIB Deep Value Analysis
TRIB Red Flags & Warning Signs
Premium- ⚠
Further equity dilution to fund operations
- ⚠
Inability to service debt leading to bankruptcy proceedings
- ⚠
Continued decline in revenue and market share
- ⚠
Increased competitive pressure in core diagnostic markets
Unlock TRIB Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
TRIB Financial Health Metrics
Market Cap
$15.30M
TRIB Competitive Moat Analysis
PremiumMoat Rating
None
Moat Trend
Eroding
Moat Sources
1 Identified
TRIB's proprietary technology and niche presence are insufficient to create a durable competitive advantage against larger, better-funded competitors who can out-innovate, out-market, and out-distribute. The moat is highly susceptible to competitive pressures and underinvestment.
TRIB Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
TRIB Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Successful restructuring of remaining debt (Q1-Q2 2026)
- •Return to positive operating cash flow (highly speculative, Q3-Q4 2026)
- •Announcement of significant new product approval or commercial launch in core segments (if funded)
Medium-Term (6-18 months)
- •Sustained period of profitability in focused diabetes/infectious disease segments (2027-2028)
- •Strategic partnership or acquisition that validates new focus (highly speculative)
- •Significant reduction in long-term debt burden
Long-Term (18+ months)
- •Successful turnaround leading to re-listing on a major exchange (2028+)
- •Development of a truly differentiated diagnostic platform gaining market share
- •Industry consolidation leading to an attractive acquisition target (speculative)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
TRIB Bull Case: What Could Go Right
- ✓
Consistent positive EBITDA and net income for several consecutive quarters
- ✓
Material reduction in total debt and interest expenses
- ✓
Announcement of a major, high-value strategic partnership or institutional investment round
- ✓
Positive cash flow from operations, indicating self-sufficiency
Bull Case Analysis
See what could go right with Premium
Never miss a move on TRIB
Create a free account to set price alerts and get notified on Telegram when TRIB hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Trinity Biotech plc (TRIB)?
As of December 30, 2025, Trinity Biotech plc has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Trinity Biotech plc?
Trinity Biotech plc's market capitalization is approximately $15.3M. The company operates in the Healthcare sector within the Medical Devices industry.
What ticker symbol does Trinity Biotech plc use?
TRIB is the ticker symbol for Trinity Biotech plc. The company trades on the NMS.
What is the risk level for TRIB stock?
Our analysis rates Trinity Biotech plc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the TRIB DVR analysis updated?
Our AI-powered analysis of Trinity Biotech plc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on December 30, 2025.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.